Does Wall Street Rate Adverum Biotechnologies Inc. (ADVM) Shares A Buy?

As of Friday close, Adverum Biotechnologies Inc.’s (NASDAQ:ADVM) stock was down -$0.07, moving down -8.06 percent to $0.84. The average number of shares traded per day over the past five days has been 1,510,100 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.1845 fall in that time frame. In the last twenty days, the average volume was 909,720, while in the previous 50 days, it was 1,168,132.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, ADVM stock retreated -29.19%. Shares of the company fell to $0.8120 on 05/13/22, the lowest level in the past month. A 52-week high of $3.86 was reached on 01/03/22 after having rallying from a 52-week low of $0.90. Since the beginning of this year, ADVM’s stock price has dropped by -52.53% or -$0.9245, and marked a new high 1 time. However, the stock has declined by -78.35% since its 52-week high.

Adverum Biotechnologies Inc. (ADVM) last reported insider trading activity 24 days ago on Apr 20. Fischer Laurent, the CEO, President and Director of the company, purchased of 25,000 shares for $1.11 on Apr 20. It resulted in a $27,800 investment by the insider. Soparkar Peter added 21,925 shares at an average price of $1.14 on Apr 19. The insider now owns 280,556 shares following the transaction. On Dec 09, CEO, President and Director Fischer Laurent bought 14,323 shares at $1.85 apiece. The transaction was valued at $26,498.

Valuation Metrics

The stock’s beta is 1.28. Besides these, the trailing price-to-sales (P/S) ratio of 11.44, the price-to-book (PB) ratio of 0.26.

Financial Health

In the three months ended December 30, Adverum Biotechnologies Inc.’s quick ratio stood at 14.90, while its current ratio was 14.90, showing that the company is able to pay off its debt. Based on annual data, ADVM earned $153.62 million in gross profit and brought in $7.5 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -46.20%. Return on equity (ROE) for the past 12 months was -40.00%.

While analysts expected Adverum Biotechnologies Inc. to report -$0.34 quarterly earnings, the actual figure was -$0.35 per share, beating the consensus estimate by -2.90%. During the quarter, the company generated -$36.5 million in EBITDA. The liabilities of Adverum Biotechnologies Inc. were 124.44 million at the end of its most recent quarter ended December 30, and its total debt was $102.99 million. The value of shareholders’ equity is $98.77 million.

Technical Picture

This quick technical analysis looks at Adverum Biotechnologies Inc.’s (ADVM) price momentum. With a historical volatility rate of 78.06%, the RSI 9-day stood at 23.00% on 13 May.

With respect to its five-day moving average, the current Adverum Biotechnologies Inc. price is down by -18.09% percent or -$0.1845. At present, ADVM shares trade -30.38% below its 20-day simple moving average and -55.08% percent below its 100-day simple moving average. However, the stock is currently trading approximately -33.16% below its SMA50 and -64.89% below its SMA200.

Stochastic coefficient K was 4.50% and Stochastic coefficient D was 9.75%, while ATR was 0.0894. Given the Stochastic reading of 6.17% for the 14-day period, the RSI (14) reading has been calculated as 27.18%. As of today, the MACD Oscillator reading stands at -0.1129, while the 14-day reading stands at -0.1399.

Analyst Ratings

Adverum Biotechnologies Inc. downgraded its rating on Adverum Biotechnologies Inc. (NASDAQ: ADVM) to a Neutral in a note to investors on July 23, 2021. The analysts firm previously had an Overweight rating on the stock.Adverum Biotechnologies Inc. (ADVM) has been rated Hold by analysts. According to 0 brokerage firms, ADVM is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Adverum Biotechnologies Inc. stock as buy, with 1 recommending it as overweight.

With a median target price of $4.00, the current consensus forecast for the stock is $3.00 – $6.00. Based on these forecasts, analysts predict Adverum Biotechnologies Inc. (ADVM) will achieve an average price target of $4.33.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles